Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is showing strong progress in its U.S. commercialization, with a successful launch, positive value analysis committee results, and continued growth in sales representatives and trained surgeons. The completion of its ACCCESS study in late June/early July 2026 could be a major catalyst for the company. Additionally, their recent combination financing of €77M, including participation from major players in the industry, shows confidence in the company's future success. However, slower initial revenue ramp and recalibration of financial models lead to a revised price target of $9.00 based on ~6x 2027 revenue estimate.

Bears say

Nyxoah is facing multiple risks including challenges with its roll-out against a market leader, potential cash flow issues, and regulatory risks associated with its ACCCESS study. Despite positive updates and a solid foundation for commercialization, these risks could hinder investor confidence and limit the company's success. Repeating orders from the 4Q25 success may provide a boost in the short term, but long-term growth and sustainability will heavily depend on the company's ability to overcome these obstacles.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.